Elevation OncologyELEV
Market Cap: $36.9M
About: Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
Employees: 29
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
150% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 12
29% more funds holding
Funds holding: 63 [Q1] → 81 (+18) [Q2]
14% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 21
4.92% more ownership
Funds ownership: 90.49% [Q1] → 95.41% (+4.92%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
38% less capital invested
Capital invested by funds: $226M [Q1] → $140M (-$85.5M) [Q2]
67% less call options, than puts
Call options by funds: $2K | Put options by funds: $6K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Swayampakula Ramakanth 36% 1-year accuracy 49 / 135 met price target | 860%upside $6 | Buy Reiterated | 7 Aug 2024 |
JMP Securities Silvan Tuerkcan 34% 1-year accuracy 14 / 41 met price target | 1,020%upside $7 | Market Outperform Reiterated | 15 Jul 2024 |
JMP Securities Silvan Tuerkcan 34% 1-year accuracy 14 / 41 met price target | 1,020%upside $7 | Market Outperform Reiterated | 28 Jun 2024 |